These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12503875)

  • 1. Improved purification and yield of the Egyptian snake Cerastes cerastes antitoxin by the use of caprylic acid.
    Seddik SS; Malak GA; Helmy MH
    J Nat Toxins; 2002 Dec; 11(4):323-8. PubMed ID: 12503875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-reagent one-step procedures for the purification of ovine IgG, F(ab')2 and Fab antivenoms by caprylic acid.
    Al-Abdulla I; Casewell NR; Landon J
    J Immunol Methods; 2014 Jan; 402(1-2):15-22. PubMed ID: 24246428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caprylic acid fractionation of hyperimmune horse plasma: description of a simple procedure for antivenom production.
    Rojas G; Jiménez JM; Gutiérrez JM
    Toxicon; 1994 Mar; 32(3):351-63. PubMed ID: 8016856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purification of F(ab')2 anti-snake venom by caprylic acid: a fast method for obtaining IgG fragments with high neutralization activity, purity and yield.
    dos Santos MC; D'Império Lima MR; Furtado GC; Colletto GM; Kipnis TL; Dias da Silva W
    Toxicon; 1989; 27(3):297-303. PubMed ID: 2728022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study on the use of caprylic acid and ammonium sulfate in combination for the fractionation of equine antivenom F(ab')(2).
    Simsiriwong P; Eursakun S; Ratanabanangkoon K
    Biologicals; 2012 Sep; 40(5):338-44. PubMed ID: 22704919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-African polyspecific antivenom produced by caprylic acid purification of horse IgG: an alternative to the antivenom crisis in Africa.
    Gutiérrez JM; Rojas E; Quesada L; León G; Núñez J; Laing GD; Sasa M; Renjifo JM; Nasidi A; Warrell DA; Theakston RD; Rojas G
    Trans R Soc Trop Med Hyg; 2005 Jun; 99(6):468-75. PubMed ID: 15837359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective efficacy of immunoglobulins Y prepared against Cerastes cerastes snake venom in the Kingdom of Saudi Arabia.
    Moussa IM; Hessan AM; Aleisa AM; Al-Arfaj AA; Salem-Bekhit MM; AlRejai SA
    Saudi Med J; 2012 Aug; 33(8):846-51. PubMed ID: 22886116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized blinded clinical trial of two antivenoms, prepared by caprylic acid or ammonium sulphate fractionation of IgG, in Bothrops and Porthidium snake bites in Colombia: correlation between safety and biochemical characteristics of antivenoms.
    Otero R; Gutiérrez JM; Rojas G; Núñez V; Díaz A; Miranda E; Uribe AF; Silva JF; Ospina JG; Medina Y; Toro MF; García ME; León G; García M; Lizano S; De La Torre J; Márquez J; Mena Y; González N; Arenas LC; Puzón A; Blanco N; Sierra A; Espinal ME; Lozano R
    Toxicon; 1999 Jun; 37(6):895-908. PubMed ID: 10340829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross neutralization of dangerous snake venoms from Africa and the Middle East using the VACSERA polyvalent antivenom. Egyptian Organization for Biological Products & Vaccines.
    Seddik SS; Wanas S; Helmy MH; Hashem M
    J Nat Toxins; 2002 Dec; 11(4):329-35. PubMed ID: 12503876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vipera palaestinae antivenin.
    Moroz C
    Public Health Rev; 1998; 26(3):233-6. PubMed ID: 10444960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irradiated Cerastes cerastes venom as a novel tool for immunotherapy.
    Oussedik-Oumehdi H; Laraba-Djebari F
    Immunopharmacol Immunotoxicol; 2008; 30(1):37-52. PubMed ID: 18306103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between therapeutic antitoxin F(ab)2 fractionated with ammonium sulfate and caprylic acid.
    Redwan el-RM
    J Immunoassay Immunochem; 2006; 27(4):319-29. PubMed ID: 16981645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of an improved method for production of antiscorpion F(ab')2 fragment of IgG with high yield and potency.
    Seddik SS; Wanas S; Shehata A; Fawaz S; Helmy MH
    J Nat Toxins; 2002 May; 11(2):123-32. PubMed ID: 12009112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on the fractionation of equine antivenom IgG by combinations of ammonium sulfate and caprylic acid.
    Eursakun S; Simsiriwong P; Ratanabanangkoon K
    Toxicon; 2012 Nov; 60(6):1022-9. PubMed ID: 22842065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical aspects on traditional antivenom production processes and their optimization by factorial analysis.
    Zurbano BN; Tavarone E; Viacava BG; Dokmetjian JC; Cascone O; Fingermann M
    Biologicals; 2020 Nov; 68():65-73. PubMed ID: 32912811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fractionation of equine antivenom using caprylic acid precipitation in combination with cationic ion-exchange chromatography.
    Raweerith R; Ratanabanangkoon K
    J Immunol Methods; 2003 Nov; 282(1-2):63-72. PubMed ID: 14604541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative comparison on the refinement of horse antivenom by salt fractionation and ion-exchange chromatography.
    Saetang T; Treamwattana N; Suttijitpaisal P; Ratanabanangkoon K
    J Chromatogr B Biomed Sci Appl; 1997 Oct; 700(1-2):233-9. PubMed ID: 9390734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticomplementary activity of equine whole IgG antivenoms: comparison of three fractionation protocols.
    León G; Lomonte B; Gutiérrez JM
    Toxicon; 2005 Jan; 45(1):123-8. PubMed ID: 15581691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of viper bites--a new antiserum based on an affinity purified F(ab) ovine immunoglobulin].
    Jacobsen P; Hein HO
    Ugeskr Laeger; 1995 Apr; 157(14):2025-6. PubMed ID: 7740651
    [No Abstract]   [Full Text] [Related]  

  • 20. Venomics and antivenomics profiles of North African Cerastes cerastes and C. vipera populations reveals a potentially important therapeutic weakness.
    Fahmi L; Makran B; Pla D; Sanz L; Oukkache N; Lkhider M; Harrison RA; Ghalim N; Calvete JJ
    J Proteomics; 2012 Apr; 75(8):2442-53. PubMed ID: 22387316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.